Ligand Pharmaceuticals Incorporated (LGND): Price-to-Revenue Ratio

Symbol and logo of brand Ligand Pharma (LGND)

Revenue multiple dynamics amid trade conflicts reveal challenges with international patenting, yet the 24.30 level records fresh values, confirming the resilience of Ligand Pharmaceuticals (LGND). Ligand Pharmaceuticals generates revenue through licensing agreements with partners, creating scientific synergy. Furthermore, the specifics of technology transfer minimize logistical risks, ensuring business stability even amidst macroeconomic instability.

Ligand Pharmaceuticals (LGND): P/S Multiple from 07/04/2022 to 11/16/2026

Metric breakdowns and analytics for Ligand (LGND)

- stock exchange capitalization data:
General company analysis:Ligand Pharma (LGND)
Signature product of ligand.com

Assessing asset reliability begins with analyzing the market capitalization to annual revenue ratio, which determines the premium paid per unit of sales. For Ligand Pharmaceuticals (LGND), this calculation confirms the efficiency of a royalty model with minimal costs; therefore, any deviation from historical P/S levels signals either an overvaluation of stable cash flows or an impending price correction.

Who Ligand Pharmaceuticals competes with

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|amneal.com (AMRX) - Market Cap to Revenue|Perrigo (PRGO) - Price-to-Revenue Ratio|ALVO (Alvotech S.A.) - Price-to-Revenue Ratio|Market Cap to Revenue LQDA|P/S Multiple Galapagos Corp|Price-to-Revenue Ratio ANI Pharma (ANIP)|P/S Multiple MannKind Corporation (MNKD)|Price-to-Revenue Ratio Amphastar Pharmaceuticals Inc AMPH|P/S Multiple Pacira PCRX|ARS Pharmaceuticals Inc - P/S Multiple|TBPH - P/S Multiple|AQST (Aquestive Therapeutics) - Market Cap to Revenue|scPharmaceuticals, Inc. (SCPH) - P/S Multiple|Market Cap to Revenue TECX|P/S Multiple Tonix Pharma|Market Cap to Revenue SXTC (SXT Pharmaceuticals)|EPRX: Price-to-Sales Ratio|BioHarvest Sciences - Market Cap to Revenue|EXOZ: Market Cap to Revenue Ratio|ORMP - Price-to-Revenue Ratio|ENTX: Price-to-Revenue Ratio|HYFT: P/S Multiple|Market Cap to Revenue ABVC BioPharma Inc|CPIX (Cumberland Corp) - P/S Multiple|P/S Multiple quantumbiopharma.com|P/S Multiple FGEN|Market Cap to Revenue Telomir Pharmaceuticals, Inc. TELO|P/S Multiple RANI (Rani Therapeutics)|SNYR (Synergy CHC Corp) - Price-to-Sales Ratio|RLYB: Market Cap to Revenue|lexariabioscience.com (LEXX) - Market Cap to Revenue|Pulmatrix Inc (PULM) - Price-to-Revenue Ratio|PTHL: Market Cap to Sales Volume|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)